Charles K. Francis

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

James H. Chesebro, Genell L. Knatterud, Robert Roberts et al. · Circulation · 1987 · 2.2K citations · Full text

Thrombosis, Hospital Discharge, Cardiovascular Disease +15

Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

J. H. Chesebro, Genell L. Knatterud, Robert Roberts et al. · 1987 · 735 citations

Thrombosis, Percutaneous Coronary Intervention, Cardiovascular Disease +14

Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease

Xian-Cheng Jiang, Furcy Paultre, Thomas A. Pearson et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2000 · 380 citations

Vascular Disease, Plasma Sm Levels, Pathology +20

Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.

David O. Williams, Jeffrey Borer, Eugene Braunwald et al. · Circulation · 1986 · 292 citations

Pharmacotherapy, Coronary Artery Disease, Myocardial Infarction Trial +18

Correlates of nonadherence to hypertension treatment in an inner-city minority population.

Steven Shea, Dawn P. Misra, Martin H. Ehrlich et al. · American Journal of Public Health · 1992 · 215 citations · Full text